BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22563027)

  • 1. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression.
    Bikker A; van Woerkom JM; Kruize AA; van der Wurff-Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
    Ann Rheum Dis; 2012 Dec; 71(12):1934-41. PubMed ID: 22563027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo CD(+) T-cell cytokine expression from patients with Sjögren's syndrome following in vitro stimulation to induce proliferation.
    Koarada S; Haruta Y; Mitamura M; Morito F; Tada Y; Ohta A; Nagasawa K
    Rheumatology (Oxford); 2006 Apr; 45(4):392-9. PubMed ID: 16287915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα.
    Bikker A; Moret FM; Kruize AA; Bijlsma JW; Lafeber FP; van Roon JA
    Rheumatology (Oxford); 2012 Jun; 51(6):996-1005. PubMed ID: 22302060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity.
    Bikker A; Kruize AA; Wenting M; Versnel MA; Bijlsma JW; Lafeber FP; van Roon JA
    Ann Rheum Dis; 2012 Jun; 71(6):1027-33. PubMed ID: 22312161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
    Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
    Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines.
    Szodoray P; Gal I; Barath S; Aleksza M; Horvath IF; Gergely P; Szegedi G; Nakken B; Zeher M
    Scand J Rheumatol; 2008; 37(3):205-12. PubMed ID: 18465456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation.
    Bikker A; van Woerkom JM; Kruize AA; Wenting-van Wijk M; de Jager W; Bijlsma JW; Lafeber FP; van Roon JA
    Arthritis Rheum; 2010 Apr; 62(4):969-77. PubMed ID: 20131250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sjögren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells.
    Eriksson P; Andersson C; Ekerfelt C; Ernerudh J; Skogh T
    J Rheumatol; 2004 Apr; 31(4):729-35. PubMed ID: 15088299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome.
    Reksten TR; Brokstad KA; Jonsson R; Brun JG; Jonsson MV
    Int Immunopharmacol; 2011 Dec; 11(12):2125-9. PubMed ID: 21964047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren's syndrome.
    Liu MF; Lin LH; Weng CT; Weng MY
    Lupus; 2008 Jan; 17(1):34-9. PubMed ID: 18089681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological consequences of thalidomide treatment in Sjögren's syndrome.
    Moutsopoulos NM; Angelov N; Sankar V; Leakan RA; Pillemer S; Wahl SM
    Ann Rheum Dis; 2006 Jan; 65(1):112-4. PubMed ID: 16344495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethanol changes gene expression of transcription factors and cytokine production of CD4+ T-cell subsets in PBMCs stimulated with LPS.
    von Haefen C; Mei W; Menk M; Klemz R; Jones A; Wernecke KD; Spies CD
    Alcohol Clin Exp Res; 2011 Apr; 35(4):621-31. PubMed ID: 21143255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome.
    Zeher M; Szodoray P; Gyimesi E; Szondy Z
    Arthritis Rheum; 1999 Aug; 42(8):1673-81. PubMed ID: 10446867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome.
    Verstappen GM; Meiners PM; Corneth OBJ; Visser A; Arends S; Abdulahad WH; Hendriks RW; Vissink A; Kroese FGM; Bootsma H
    Arthritis Rheumatol; 2017 Sep; 69(9):1850-1861. PubMed ID: 28564491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of T-cell large granular lymphocyte leukemia associated with Sjogren's syndrome-an important but under-recognized association.
    Friedman J; Schattner A; Shvidel L; Berrebi A
    Semin Arthritis Rheum; 2006 Apr; 35(5):306-11. PubMed ID: 16616153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
    Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
    Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.
    Zhou J; Yu Q
    Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2438-2447. PubMed ID: 29680668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.